$PM

PM vs. MO: The Smoke-Free Dividend Winner in This Tobacco Showdown

Philip Morris (PM) raised its quarterly dividend by 9% to $1.60, while Altria (MO) increased its dividend by 5% to $1.11. PM's revenue grew 10.4% in Q2, with 42% from smoke-free products. PM's adjusted EPS guidance for 2026 is $8.26-$8.41, reflecting 9.5%-11.5% growth. Altria's guidance is $5.61-$5.72, with 3.5%-5.5% growth. Altria offers a higher yield (6.15%) but faces declining cigarette volumes and $2.2B in e-vapor impairments.

Original reporting
Published Sep 25, 2026, 3:15 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 25, 2026, 3:32 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
PM vs. MO: The Smoke-Free Dividend Winner in This Tobacco Showdown — source image
Decision brief

The 30-second read

$PMBullishMed
01

Why it matters

Higher dividend and guidance for PM suggest a bullish case for long‑term investors, while MO's yield appeal may attract short‑term income seekers.

02

Market read

Both stocks are dividend‑focused plays; PM's growth narrative may shift sector dynamics, while MO remains a high‑yield option.

03

What to watch

Potential regulatory risks to ZYN and IQOS products could affect PM's growth outlook.

Relevance 6/10Novelty 6/10Timing: post‑dividend announcement Sep 18

Background

The article compares dividend hikes and guidance for the two largest U.S. tobacco companies, focusing on smoke‑free product growth versus traditional cigarette decline.

Company-level read

Ticker impact

$PMBullishMedium confidence
Context

Philip Morris raised its quarterly dividend to $1.60 and lifted 2026 EPS guidance to $8.26‑$8.41, indicating stronger cash flow and growth.

Expected impact

Potential upside of 3‑5% over the next few weeks.

Evidence & confidence

Guidance and dividend increase are fresh disclosures; market has not fully priced the growth runway.

$MONeutralLow confidence
Context

Altria increased its quarterly dividend to $1.11 and provided 2026 earnings guidance of $5.61‑$5.72, while noting $2.2 B e‑vapor impairments.

Expected impact

Limited upside, likely 1‑2% rally for yield‑seeking investors.

Evidence & confidence

Yield increase is positive, but long‑term growth concerns temper enthusiasm.

Market effects

Highlights shift toward smoke‑free products in tobacco sector, may pressure peers to accelerate similar transitions.

International revenue growth for PM could benefit exposure to emerging markets.

Dividend and guidance updates are relevant for global income‑focused funds.

Counterpoint

Altria's higher current yield may still outperform if smoke‑free transition stalls.

Key entities

  • Philip Morris International

    US‑listed tobacco company (PM) raising dividend and guidance.

  • Altria Group

    US‑listed tobacco company (MO) raising dividend with modest guidance.

Related articles

$MOMed

Trump administration plans to speed approvals of vapes and nicotine pouches - WSJ

The Trump administration plans to speed up approvals for smoke-free nicotine products like vapes and nicotine pouches, easing FDA review requirements. This benefits tobacco companies such as Altria (MO), Philip Morris (PM), and British American Tobacco (BTI), which face regulatory delays. The move aims to reduce illegal products but faces opposition from health advocates concerned about youth access.

$PMHighAI 8/10

Why is Philip Morris International stock climbing today?

Philip Morris International (PM) stock rose 2.1% after updating its Q3 2026 EPS guidance to $2.29-$2.34, exceeding estimates. The company also raised its full-year 2026 EPS forecast to $8.35-$8.50, citing favorable currency impacts. Analysts increased price targets to $205-$225. PM's defensive profile and smoke-free products supported the stock amid broader market declines.

$PMMedAI 8/10

FDA Authorization Expands Philip Morris’s Zyn Bet, Can It Pay Off?

Philip Morris (NYSE:PM) received FDA authorization for 11 nicotine-pouch products, including higher-strength Zyn Ultra pouches. The company aims to expand its market share in the fastest-growing US nicotine category, but lower pricing and increased investment may impact profitability. The FDA cited lower harmful constituents compared to other tobacco products. PM plans to invest more in Zyn as competition intensifies, particularly against British American Tobacco's Velo brand. However, the succe

$PMMedAI 8/10

PM Looks 16.9% Overvalued on GF Value™ as Dividend Sustainabilit

Philip Morris International (NYSE: PM) raised its full-year adjusted diluted EPS forecast to $7.28-$7.43, reflecting 10.7%-12.7% growth. CEO Jacek Olczak highlighted strong pricing power and profit growth at the Barclays Global Consumer Conference. The stock, trading at $185.07, is 16.9% overvalued relative to its GF Value™ of $158.36, with a 3.16% dividend yield and a 73% payout ratio.